Klinea is a B Corp
The engineering solutions development company for the pharmaceutical and biotechnology sector is clear that the future of the industry must be built on a strong commitment to sustainability values.
In today’s context, where sustainability has become a cornerstone of the pharmaceutical industry, Klinea stands out for its strong commitment to responsible and sustainable practices. We spoke with Joan Cano, Head of the Utilities & Process Department at Klinea.
“From a pharmaceutical engineering perspective, the challenge we face is to contribute as much knowledge as possible to the projects we design, in order to reduce the CO₂ footprint and support the planet’s sustainability,” says Joan Cano.
These challenges are part of Klinea’s day-to-day operations, as the company consistently integrates cutting-edge technologies and the most advanced sustainability criteria across its projects, thereby reinforcing its strategic commitment to a more responsible and efficient future.
Klinea and B Corp: a unique opportunity to lead a global movement through pharmaceutical engineering
As a certified B Corp, Klinea is part of a global community of companies that meet high standards of social and environmental impact. Systemic change cannot be achieved by a single company alone, which is why B Corps lead collectively, as a Movement.
Klinea is distinguished as the first engineering firm within the pharmaceutical sector to achieve B Corp certification. The company, a developer of engineering solutions for the pharmaceutical and biotechnology industries, is clear that the sector’s future must be built on a firm commitment to sustainability values.
In line with this vision, Klinea not only incorporates ESG (environmental, social, and governance) criteria into its supplier approval process—strengthening sustainable management across its entire value chain—but also sets clear goals for the coming years. These include the launch of a strategic sustainability plan, the publication of its first sustainability report in 2025, and the development of an internal tool to measure and manage environmental impact.
Through these initiatives, the engineering and biotechnology company reaffirms its commitment to generating a positive and lasting impact on the pharmaceutical industry, moving towards a more responsible, innovative business model aligned with global sustainability challenges.